Assembly Biosciences Inc (ASMB) - News Archive

Innovative Therapeutics in Virology: Assembly Biosciences Unveils Promising Data on Capsid Assembly Modulators and Novel InhibitorsIn the realm of antiviral research, Assembly Biosciences has emerged as a significant pl...

Advancements and Challenges: Assembly Biosciences’ Phase 1b Data for ABI-5366 and Market Dynamics In recent developments within the biotechnology realm, Assembly Biosciences Inc. has made significant strides with their...

In an era marked by significant advancements in antiviral therapy, Assembly Biosciences has unveiled pivotal data at the 2025 European Congress of Clinical Microbiology and Infectious Diseases (ESCMID) that could reshap...

Advances in Hepatitis B and Herpes Simplex Virus Therapeutics: Assembly Biosciences Promising Trials Assembly Biosciences has made significant progress in its clinical development pipeline for antiviral therapies target...

Assembly Biosciences, a leading biotechnology company focused on developing innovative treatments for viral infections, recently presented new preclinical data at the International Herpesvirus Workshop. The data showcas...

Assembly Biosciences, a biotechnology company focused on developing therapeutics for serious viral diseases, has recently announced the initiation of a Phase 1b clinical trial evaluating their next-generation capsid ass...

1. Assembly Biosciences Secures $12.6 Million in Equity Financing to Propel Antiviral Portfolio and Extend Cash RunwayAssembly Biosciences, a leading biotechnology company, recently announced the successful completion o...

Assembly Biosciences, a clinical-stage biotechnology company, has recently announced the dosing of the first participant in a Phase 1a/b clinical trial for their herpes simplex virus (HSV) helicase-primase inhibitor can...

Promising Preclinical Data for Hepatitis D Virus Entry Inhibitor ABI-6250 Presented at EASL Congress 2024 The treatment of Hepatitis D Virus (HDV) infection, one of the most severe forms of viral hepatitis, remains an a...

In recent reports emanating from the biotech sector, Assembly Biosciences, Inc. (Nasdaq: ASMB) disclosed their financial results for the first quarter of the year 2024, which wrapped up on March 31, 2024. Operating from...

Assembly Bio common stock is expected to commence trading on a split-adjusted basis on February 12, 2024, paving the way for potential changes in the market dynamic and its impact on existing shareholders. This announce...

Assembly Biosciences Outlines Anticipated Development Milestones for 2024; Strong Progress Expected for Clinical PipelineAssembly Biosciences, a renowned biotechnology company specializing in the development of innovati...